LIORESAL INTRATHECAL 0.5MG/ML 0.5 MG — DIN 02131056
BACLOFEN : 0.5 MG · NOVARTIS PHARMACEUTICALS CANADA INC · SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is LIORESAL INTRATHECAL 0.5MG/ML?
LIORESAL INTRATHECAL 0.5MG/ML 0.5 MG contains BACLOFEN : 0.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02131056, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as SOLUTION for INTRATHECAL administration. Health Canada currently lists it as cancelled post market, status dated 28-Aug-2023. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is LIORESAL INTRATHECAL 0.5MG/ML used for?
Management of severe spasticity due to spinal cord injury or multiple sclerosis unresponsive to oral baclofen or with unacceptable side effects. Alternative to neurosurgical procedures.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Baclofen cost around the world?
Baclofen is listed on 10 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 7 | 127 | USD███.██ |
| Australia | ex-manufacturer | 10 | 24 | AUD███.██ |
| Saudi Arabia | public | 11 | 14 | SAR███.██ |
| South Africa | single exit price | 12 | 13 | ZAR███.██ |
| United Kingdom | hospital | 7 | 7 | GBP███.██ |
| Bahrain | retail (max) | 4 | 6 | BHD███.██ |
| Greece | producer price (ex-factory) | 5 | 5 | EUR███.██ |
| United Arab Emirates | public | 4 | 4 | AED███.██ |
| Hungary | producer price (ex-factory) | 4 | 4 | HUF███.██ |
| Romania | max producer price | 2 | 4 | RON███.██ |
208 pack listings across 66 brand entries and 8 price bases, refreshed 08 Sep 2026. Ranges span every Baclofen pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Baclofen in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
25 holders have a Canadian DIN containing Baclofen, across 59 DINs, of which 23 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| JAMP PHARMA CORPORATION | 3 | 3 | BACLOFEN INJECTION USP, JAMP BACLOFEN | Sourceable in Canada |
| STERIMAX INC | 3 | 3 | BACLOFEN INJECTION | Sourceable in Canada |
| APOTEX INC | 4 | 2 | APO-BACLOFEN, BACLOFEN | Sourceable in Canada |
| AVIR PHARMA INC. | 3 | 2 | BACLOFEN INTRATHECAL | Sourceable in Canada |
| LABORATOIRE RIVA INC. | 2 | 2 | RIVA-BACLOFEN | Sourceable in Canada |
| MYLAN PHARMACEUTICALS ULC | 2 | 2 | MYLAN-BACLOFEN | Sourceable in Canada |
| PHARMASCIENCE INC | 2 | 2 | PMS-BACLOFEN | Sourceable in Canada |
| PRO DOC LIMITEE | 2 | 2 | PRO-BACLOFEN | Sourceable in Canada |
| SANIS HEALTH INC | 2 | 2 | BACLOFEN | Sourceable in Canada |
| SIVEM PHARMACEUTICALS ULC | 2 | 2 | BACLOFEN | Sourceable in Canada |
| HIKMA CANADA LIMITED | 3 | 1 | BACLOFEN INJECTION | Sourceable in Canada |
| NOVARTIS PHARMACEUTICALS CANADA INC | 5 | 0 | LIORESAL D.S. TAB 20MG, LIORESAL INTRATHECAL 0.05MG/ML, LIORESAL INTRATHECAL 0.5MG/ML, LIORESAL INTRATHECAL 2MG/ML, LIORESAL TAB 10MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 0.5 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRATHECAL |
| Pack configuration (monograph) | Not explicitly detailed in provided text (mentions 0.05 mg/mL, 0.5 mg/mL and 2 mg/mL concentrations). |
| Storage | Not explicitly detailed in provided text. |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Baclofen |
|---|---|
| ATC code | M03BX01 |
| AHFS class | 12:20.12 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02131056 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2131056 |
| Brand name | LIORESAL INTRATHECAL 0.5MG/ML |
| Generic / active ingredient | BACLOFEN : 0.5 MG |
| Market authorization holder | NOVARTIS PHARMACEUTICALS CANADA INC |
| Health Canada schedule | Prescription |
| ATC code | M03BX01 |
| ATC anatomical main group | M — Musculo-skeletal system |
| ATC therapeutic subgroup | M03BX |
| Current status | CANCELLED POST MARKET |
| Status date | 28-Aug-2023 |
| Original market date | 1994-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Must be administered via screening trial (bolus) before pump implantation. Chronic infusion via implantable pump. Titrate gradually to maintain effectiveness. Requires medical supervision.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Known or suspected hypersensitivity to baclofen or any excipients. Not for intravenous, intramuscular, subcutaneous, or epidural administration.
Warnings and precautions
Risk of life-threatening CNS depression, cardiovascular collapse, respiratory failure. Abrupt withdrawal can cause high fever, altered mental status, rebound spasticity, and death.
Is Baclofen in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Discontinued — reported by AVIR PHARMA INC., last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
23 of 59 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-BACLOFEN | 10 MG | TABLET | APOTEX INC | MARKETED | 02139332 |
| APO-BACLOFEN | 20 MG | TABLET | APOTEX INC | MARKETED | 02139391 |
| BACLOFEN | 10 MG | TABLET | SANIS HEALTH INC | MARKETED | 02287021 |
| BACLOFEN | 20 MG | TABLET | SANIS HEALTH INC | MARKETED | 02287048 |
| BACLOFEN | 20 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | 02544679 |
| BACLOFEN | 10 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | 02544660 |
| BACLOFEN INJECTION | 10 MG / 5 ML | SOLUTION | STERIMAX INC | MARKETED | 02413647 |
| BACLOFEN INJECTION | 0.05 MG / 1 ML | SOLUTION | STERIMAX INC | MARKETED | 02413620 |
| BACLOFEN INJECTION | 10 MG / 20 ML | SOLUTION | STERIMAX INC | MARKETED | 02413639 |
| BACLOFEN INJECTION | 2 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | 02457075 |
2 · Same class — other molecules in ATC M03BX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Baclofen | APO-BACLOFEN · AVA-BACLOFEN · BACLOFEN · BACLOFEN INJECTION · +29 more | 59 | 23 | Yes |
| Cyclobenzaprine | AG-CYCLOBENZAPRINE · ALTI-CYCLOBENZAPRINE - TAB 10MG · APO-CYCLOBENZAPRINE · AURO-CYCLOBENZAPRINE · +15 more | 23 | 10 | Yes |
| Tizanidine | APO-TIZANIDINE · MINT-TIZANIDINE · MYLAN-TIZANIDINE · PAL-TIZANIDINE | 5 | 2 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC M03B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| M03BA | Methocarbamol · Methocarbamol, Combinations Excl Psycholeptics | 76 | 14 |
| M03BC | Orphenadrine (Citrate) · Orphenadrine, Combinations | 7 | 1 |
| M03BB | Chlorzoxazone, Combinations Excl Psycholeptics | 8 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is LIORESAL INTRATHECAL 0.5MG/ML called?
The same molecule, Baclofen, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| APO-Baclofen | Latin | Australia |
| Baclon | Latin | Bahrain, Saudi Arabia |
| Sintetica Baclofen Intrathecal | Latin | Australia |
| BACLOCALM | Latin | Bahrain |
| Bacthecal | Latin | Australia |
| Bastix | Latin | Saudi Arabia |
| Lioresal | Latin | Bahrain, South Africa |
| Lioresal Intrathecal | Latin | Australia |
| Loanta | Latin | Bahrain, Saudi Arabia |
| baclocan | Latin | Saudi Arabia |
| Baclofen | Latin | Saudi Arabia |
| Baclofen Crescent | Latin | Saudi Arabia |
| Bio-Baclofen | Latin | South Africa |
| Fenozyd | Latin | South Africa |
| Spasifen | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.